AUG 07, 2018 8:30 PM PDT

Potential Bcl-2 Targeted Therapy for Relapsed Multiple Myeloma Patients

WRITTEN BY: Mauri Brueggeman

In June 2018, a new first of its kind drug class for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) was approved by the Food and Drug Administration in the United States.  The target of this new drug class is Bcl-2, which is an apoptotic, or programmed cell death, regulator.  Bcl-2 controls cell death through mitochondrial membrane permeability mechanisms with caspases.  Bcl-2 is located on chromosome 18, and is considered an oncogene; this sequence can, and is, involved in translocations or mutations resulting in deregulation of expression in tumorigenesis.  Tumor cells must survive inhospitable conditions including hypoxia and loss of nutrient supply when they become advanced enough; each of these contribute to tumor cell damage susceptibility and apoptosis.  Tumor cells must adapt by gaining mutations that inhibit that apoptotic process which is what happens with Bcl-2 mutations. 

Bcl-2 family members, there are reported to be about 20 total related proteins, act to create protein channels or pores within the mitochondrial membrane allowing the release of factors like Cytochrome C.  These factors are intermediaries as part of one apoptotic pathway.  When Bcl-2 expression is affected by mutation, these factors cannot be released as a part of the apoptosis mechanism of the cell.

In mutated lymphocytic cells, there is high level of expression of proapoptotic proteins at the ready but they are stuck waiting by the blocked Bcl-2 pathway.  Patients with these primed mutated lymphocytes, like those with CLL, readily die when another apoptotic agent outside of that Bcl-2 mediated pathway is introduced in conjunction with this new drug class. 

Additional investigations are being made using Bcl-2 targeted drugs for other conditions like Multiple Myeloma (MM), which does not involve an altered chromosome 18; MM cells are plasma cells with a translocation between chromosomes 11 and 14.  However, one group of researchers published their investigation in Leukemia on August 3, 2018.  MM patients have overexpression of anti-apoptotic proteins like Bcl-2; they found that combination therapy which included venetoclax, the Bcl-2 targeted drug approved by the FDA in June, had a promising response rate in relapsed myeloma patients.  This type of pretreated myeloma patient has few options for disease free survival long term.  This new approach may prove to be clinically relevant in the near future after further research is conducted.  

Sources: Leukemia, Blood, FDA, BBA Molecular Cell Research,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
MAR 18, 2020
Drug Discovery & Development
MAR 18, 2020
Drug Could Effectively Treat a Lethal Blood Cancer
A pricey drug, called tyrosine kinase inhibitor (TKI), is used to continuously treat the blood cancer Chronic Myeloid Le ...
APR 06, 2020
Immunology
APR 06, 2020
Clearing the Path for Dendritic Cells to Eliminate Tumors
  Dendritic cells are the sentinels of the immune system and use their “tree-like” projections to prese ...
APR 12, 2020
Cancer
APR 12, 2020
Understanding the link between obesity and breast cancer
A researcher from the James Graham Brown Cancer Center at the University of Louisville claims to have figured out the mo ...
MAY 02, 2020
Cancer
MAY 02, 2020
Tracking DNA Methylation as a Prognostic Marker
In the modern age of biological research, one of the tools that have become readily available in the ever-increasing dat ...
MAY 14, 2020
Clinical & Molecular DX
MAY 14, 2020
New Tech Has Its AI on Brain Tumors
  A collaboration across 29 research and healthcare agencies is putting together the world’s largest brain tu ...
MAY 26, 2020
Genetics & Genomics
MAY 26, 2020
Some People May be Predisposed to Metastasis if They Get Cancer
Cancer can occur for many reasons and is influenced by many different factors, including genes and the environment. But ...
Loading Comments...